Hypo-osmotic stress inhibits doxorubicin-induced apoptosis via a protein kinase A-dependent mechanism in cardiomyocytes.
1. The clinical use of doxorubicin is limited by the development of severe cardiomyopathies linked, at least in part, to an abnormal increase in the rate of apoptotic cell death. Because cell shrinkage is considered to be a crucial step at the onset of apoptosis, the aim of the present study was to investigate whether a brief hypo-osmotic stress, which leads to an increase in cell volume, could interfere with the induction of apoptosis by doxorubicin in adult cardiomyocytes. 2. Cell volume expansion results in intracellular accumulation of cAMP, so we secondarily tested whether the protective effect of hypo-osmotic stress could be related to the cAMP pathway. Accordingly, apoptosis was induced by doxorubicin (1 micromol/L) in cardiomyocytes freshly isolated from New Zealand adult rabbit hearts. 3. Exposure to doxorubicin in an iso-osmotic medium (290 mOsmol/kg H2O) induced a rapid decrease in cell volume, as well as increases in annexin V labelling and caspase-3 activity, two biological markers of apoptosis. These effects of doxorubicin were abolished by 15 min pretreatment with hypo-osmotic stress at 220 mOsmol/kgH2O (HS 220). 4. This cytoprotective effect of HS 220 was still observed when doxorubicin was added to the medium 60 min later, but it was abolished when the pretreatment by HS 220 was associated with the protein kinase A inhibitor KT 5720 (200 nmol/L). 5. Conversely, 15 min pretreatment with either the cAMP analogue 8-bromo-cAMP (0.5 mmol/L) or the adenylate cyclase activator forskolin (10 micromol/L) inhibited apoptosis induced by doxorubicin. 6. In conclusion, these results demonstrate that: (i) apoptosis induced by doxorubicin can be counteracted by a hypo-osmotic stress in adult cardiomyocytes; and (ii) activation of the protein kinase A-dependent pathway plays a major role in the mechanism leading to the cytoprotective effect induced by a hypo-osmotic stress.
d'Anglemont de Tassigny
Alexandra
A
Laboratoire de Pharmacologie, Faculté de Médecine de Créteil, Université Paris XII, France.
Ghaleh
Bijan
B
Souktani
Rachid
R
Henry
Patrick
P
Berdeaux
Alain
A
D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000494:pharmacology; D000818:Animals; D017304:Annexin A5 / Q000378:metabolism; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D002469:Cell Separation; D048429:Cell Size / Q000187:drug effects; D000242:Cyclic AMP / Q000378:metabolism; D017868:Cyclic AMP-Dependent Protein Kinases / Q000502:physiology*; D004317:Doxorubicin / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000378:metabolism; D066298:In Vitro Techniques; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000502:physiology*; D009997:Osmotic Pressure; D011817:Rabbits
D017304:Annexin A5; D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D015124:8-Bromo Cyclic Adenosine Monophosphate; D004317:Doxorubicin; D000242:Cyclic AMP; D017868:Cyclic AMP-Dependent Protein Kinases; D053148:Caspase 3; D020169:Caspases